LOWELL, Mass.--(BUSINESS WIRE)--The United States Patent and Trademark Office recently issued patent 12,178,937 entitled “Compositions and Methods for Adhesion to Surfaces,” which constitutes the 10^th U.S. patent that covers the TETRANITE bone adhesive technology. This patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. The issuance of this patent complements RevBio’s existing U.S. patent 11,638,777, which covers the method of repairing fractured bone using the aforementioned adhesive composition. These recently issued patents enlarge RevBio’s portfolio of adhesive compositions for bone repair. The novel TETRANITE biomaterial is also the only patented bone adhesive to include phosphoserine, an organic compound, which has been shown in published literature to play a role in the process of bone regeneration.

"The granting of this patent continues to expand RevBio's controlling intellectual property estate in the mineral-organic bone adhesive space. This novel and very promising biomaterial distinctively combines excellent handling characteristics, weight-bearing strength, and high biocompatibility with unique adhesive and bone regenerative properties," said George Kay, DMD, Chief Scientific Officer and co-founder of RevBio, Inc.

RevBio (formerly known as LaunchPad Medical) obtained an exclusive worldwide patent license from Stryker Corporation (NYSE: SYK) to six patent families which cover the bone adhesive technology composition and specific methods for its use. These issued patent families provide patent protection through 2033, resulting in a lengthy period of protection for RevBio to develop and market TETRANITE-based products.

Since 2016, RevBio has filed fourteen Patent Cooperation Treaty (PTC) patent applications to protect and expand its robust and growing patent portfolio for which many of these patents will provide protection of its bone adhesive platform through the year 2043. Four of these applications have issued as U.S. patents while the majority of these applications have published and are at various stages of prosecution in such countries and jurisdictions as the United States, multiple European Union countries, Canada, Australia, Japan, and China. These patent families provide patent coverage for RevBio’s product pipeline, such as compositions including derivatives to the original TETRANITE bone adhesive, expanded methods of use, ancillary devices, and key packaging components.

“As a clinical stage company, it is exciting to receive this key patent that expands patent protection for the full spectrum of indications we are pursuing,” said Brian Hess, CEO and founder of RevBio, Inc. “This new patent will enhance the company’s core value and competitive advantage for our investors who are funding the development of this game-changing technology platform.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.